Accordingly, a combination approach involving IL-10 and C3aR/C5aR antagonists could serve as an effective therapeutic strategy for immune-resistant cancers, particularly when augmented with the addition of IL-2 [IL-10 + IL-2 + C3aR/C5aR signaling blockade] [109]. Here, C3AR1 is linked to cancer.